Elusive potential of neurotrophic factors

The failure of Amgen-Regeneron Partners' brain-derived neurotrophic factor in amyotrophic lateral sclerosis (ALS), delivered subcutaneously, was a reminder of the difficulties researchers have faced in developing neurotrophic factors. While the risks of developing BDNF and other neurotrophic factors remain substantial, scientists continue to believe the chance is worth taking.

Both the enthusiasm about neurotrophic factors and the problems in figuring out how to use them derive in part from the way they were discovered. "Most of this is based initially on the biology of these molecules - nerve growth factor was first - and their role in the development of the nervous system,"

Read the full 1027 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE